- Home
- CADL vs EDD Comparison
CADL vs EDD Comparison
Compare CADL & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CADL | EDD |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.3M | 397.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | EDD |
|---|---|---|
| Price | $4.67 | $5.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 489.5K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $4.28 |
| 52 Week High | $9.08 | $6.18 |
Technical Indicators
Market Signals| Indicator | CADL | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 28.18 |
| Support Level | $4.57 | $5.45 |
| Resistance Level | $6.16 | $5.69 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 5.06 | 14.29 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.